Pancreatic Cancer Screening and Management

Screening Recommendations

The European Society for Medical Oncology recommends that screening for pancreatic cancer is only indicated for individuals with specific genetic or familial risk factors, not occupational exposures 2
First-degree relatives from familial pancreatic cancer kindreds with at least two affected first-degree relatives should be screened 2
Genetic syndrome carriers, including Peutz-Jeghers syndrome, BRCA2 mutation carriers, p16 mutation carriers, Hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers, and Hereditary pancreatitis syndrome, should be screened 1, 2

The American Gastroenterological Association recommends initial imaging with ultrasound of liver, bile duct, and pancreas without delay when pancreatic malignancy is suspected 4
Definitive staging should include Multi-detector CT (MD-CT) or MRI plus MRCP 4
Chest imaging with MD-CT of chest should be performed to evaluate for lung metastases 4

The National Comprehensive Cancer Network recommends radical surgery as the only curative treatment option for resectable disease (Stage I and Some Stage II) 4
Pancreaticoduodenectomy (with or without pylorus preservation) is recommended for pancreatic head tumors 4
Distal pancreatectomy with splenectomy is recommended for body and tail tumors 4
Surgery should be performed at high-volume specialist centers to reduce morbidity and mortality 2, 4

The European Society for Medical Oncology recommends endoscopic stenting as the preferred method for managing biliary obstruction 5, 4
Metal stents are recommended for life expectancy >3 months 5, 4
Plastic stents should be replaced every 6 months 5
Opioids (morphine) are recommended as first-line treatment for severe pain, with oral route preferred 5, 4

The American Society of Clinical Oncology recommends CA19.9 monitoring every 3 months for 2 years for patients with elevated preoperative CA19.9 5, 4
Abdominal CT scan should be performed every 6 months 5, 4
Toxicity assessment should be performed at each cycle for patients on chemotherapy 6
Response evaluation with imaging should be performed every 8 weeks 6